펩타이드 치료제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)
Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
상품코드:1742550
리서치사:Transparency Market Research
발행일:2025년 04월
페이지 정보:영문 257 Pages
라이선스 & 가격 (부가세 별도)
한글목차
펩타이드 치료제 시장 - 조사 범위
TMR의 조사 보고서 "세계 펩타이드 치료제 시장"은 2025-2035년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서는 2019년부터 2035년까지의 세계 펩타이드 치료제 시장의 수익과 예측을 제공하는데, 2025년을 기준 연도로, 2035년을 예측 연도로 삼고 있습니다. 또한, 2025-2035년까지의 세계 펩타이드 치료제 시장의 연평균 성장률도 제시합니다.
이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서 애널리스트는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 인터뷰를 진행했습니다. 2차 조사에서는 주요 기업의 제품 자료, 연례 보고서, 보도 자료, 관련 자료 등을 참고하여 펩타이드 치료제 시장을 이해하고자 했습니다.
시장 현황
2024년 시장 규모
453억 달러
2035년 시장 규모
1,232억 달러
CAGR
9.5%
이 보고서는 세계 펩타이드 치료제 시장의 경쟁 환경을 조사하고 있습니다. 세계 펩타이드 치료제 시장에서 활동하는 주요 기업들이 확인되었으며, 각 기업들은 다양한 특성으로 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향, SWOT는 세계 펩타이드 치료제 시장의 기업들이 이 보고서에서 소개하는 속성입니다.
목차
제1장 서문
제2장 가정과 조사 방법
제3장 주요 요약
제4장 시장 개요
소개
개요
시장 역학
세계의 펩타이드 치료제 시장 분석과 예측, 2020-2035년
제5장 주요 인사이트
FDA에 의한 펩타이드 치료제 승인(2024년)
2000년 이후에 승인된 펩타이드 의약품과 그 표적 및 적응증
화이트 스페이스 분석
Porters 분석
파이프라인 분석
펩타이드 의약품 화학 구조 동향 분석
펩타이드 의약품에 사용되는 분리 매체
업계 미충족 수요
제6장 세계의 시장 분석과 예측 : 제품 유형별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 제품 유형별, 2020-2035년
혁신
제네릭
시장 매력 : 제품 유형별
제7장 세계의 시장 분석과 예측 : 용도별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 용도별, 2020-2035년
대사
종양학
위장
심혈관계
신경학적
기타
시장 매력 : 용도별
제8장 세계의 시장 분석과 예측 : 투여 경로별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 투여 경로별, 2020-2035년
비경구
경구
기타
시장 매력 : 투여 경로별
제9장 세계의 시장 분석과 예측 : 펩타이드 유형별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 펩타이드 유형별, 2020-2035년
천연 펩타이드
유사 펩타이드
이종 펩타이드
시장 매력 : 펩타이드 유형별
제10장 세계의 시장 분석과 예측 : 기술별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 기술별, 2020-2035년
액상
고상
하이브리드
시장 매력 : 기술별
제11장 세계의 시장 분석과 예측 : 제조 유형별
소개와 정의
주요 조사 결과/진전
시장 금액 예측 : 제조 유형별, 2020-2035년
사내
CMO
시장 매력 : 제조 유형별
제12장 세계의 시장 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장 매력 : 지역별
제13장 북미의 시장 분석과 예측
미국
캐나다
제14장 유럽의 시장 분석과 예측
독일
영국
프랑스
스페인
이탈리아
기타 유럽
중국
일본
인도
호주와 뉴질랜드
기타 아시아태평양
제15장 아시아태평양 시장 분석과 예측
중국
일본
인도
호주·뉴질랜드
기타 아시아태평양
제16장 라틴아메리카의 시장 분석과 예측
브라질
멕시코
기타 라틴아메리카
제17장 중동 및 아프리카의 시장 분석과 예측
GCC 국가
남아프리카공화국
기타 중동 및 아프리카
제18장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
시장 점유율 분석 기업별(2024년)
기업 개요
Amgen, Inc.
Sachem Holding AG
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Novartis AG
Pfizer, Inc.
Sanofi
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
KSM
영문 목차
영문목차
Peptide Therapeutics Market - Scope of Report
TMR's report on the global peptide therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global peptide therapeutics market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global peptide therapeutics market from 2025 to 2035.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the peptide therapeutics market.
Market Snapshot
Market Value in 2024
US$ 45.3 Bn
Market Value in 2035
US$ 123.2 Bn
CAGR
9.5%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global peptide therapeutics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global peptide therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global peptide therapeutics market.
The report delves into the competitive landscape of the global peptide therapeutics market. Key players operating in the global peptide therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global peptide therapeutics market profiled in this report.
Key Questions Answered in global peptide therapeutics Market Report:
What is the sales/revenue generated by peptide therapeutics across all regions during the forecast period?
What are the opportunities in the global peptide therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2035?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Peptide Therapeutics Market - Research Objectives and Research Approach
The comprehensive report on the global peptide therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global peptide therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global peptide therapeutics market.
Table of Contents
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Peptide Therapeutics Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Peptide Therapeutics Market Analysis and Forecasts, 2020-2035
5. Key Insights
5.1. FDA-approved Peptide Therapeutics in 2024
5.2. Peptide Drugs Approved Since 2000, with their Targets and Indications
5.3. White Space Analysis
5.4. Porter's Analysis
5.5. Pipeline Analysis
5.6. Peptide Drugs Chemical Structure Trend Analysis
5.7. Separation Media Used for Peptide Drugs
5.8. Unmet Needs of the Industry
6. Global Peptide Therapeutics Market Analysis and Forecasts, By Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product Type, 2020-2035
6.3.1. Innovative
6.3.2. Generic
6.4. Market Attractiveness By Product Type
7. Global Peptide Therapeutics Market Analysis and Forecasts, By Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Application, 2020-2035
7.3.1. Metabolic
7.3.2. Oncology
7.3.3. Gastrointestinal
7.3.4. Cardiovascular
7.3.5. Neurological
7.3.6. Others
7.4. Market Attractiveness By Application
8. Global Peptide Therapeutics Market Analysis and Forecasts, By Route of Administration
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Route of Administration, 2020-2035
8.3.1. Parenteral
8.3.2. Oral
8.3.3. Others
8.4. Market Attractiveness By Route of Administration
9. Global Peptide Therapeutics Market Analysis and Forecasts, By Types of Peptide
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Types of Peptide, 2020-2035
9.3.1. Native Peptides
9.3.2. Analog Peptides
9.3.3. Heterologous Peptides
9.4. Market Attractiveness By Types of Peptide
10. Global Peptide Therapeutics Market Analysis and Forecasts, By Technology
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By Technology, 2020-2035
10.3.1. Liquid Phase
10.3.2. Solid Phase
10.3.3. Hybrid
10.4. Market Attractiveness By Technology
11. Global Peptide Therapeutics Market Analysis and Forecasts, By Manufacturing Type
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Value Forecast By Manufacturing Type, 2020-2035
11.3.1. In-house
11.3.2. CMO
11.4. Market Attractiveness By Manufacturing Type
12. Global Peptide Therapeutics Market Analysis and Forecasts, By Region
12.1. Key Findings
12.2. Market Value Forecast By Region
12.2.1. North America
12.2.2. Europe
12.2.3. Asia Pacific
12.2.4. Latin America
12.2.5. Middle East & Africa
12.3. Market Attractiveness By Region
13. North America Peptide Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Product Type, 2020-2035
13.2.1. Innovative
13.2.2. Generic
13.3. Market Value Forecast By Application, 2020-2035
13.3.1. Metabolic
13.3.2. Oncology
13.3.3. Gastrointestinal
13.3.4. Cardiovascular
13.3.5. Neurological
13.3.6. Others
13.4. Market Value Forecast By Route of Administration, 2020-2035
13.4.1. Parenteral
13.4.2. Oral
13.4.3. Others
13.5. Market Value Forecast By Types of Peptide, 2020-2035
13.5.1. Native Peptides
13.5.2. Analog Peptides
13.5.3. Heterologous Peptides
13.6. Market Value Forecast By Technology, 2020-2035
13.6.1. Liquid Phase
13.6.2. Solid Phase
13.6.3. Hybrid
13.7. Market Value Forecast By Manufacturing Type, 2020-2035
13.7.1. In-house
13.7.2. CMO
13.8. Market Value Forecast By Country, 2020-2035
13.8.1. U.S.
13.8.2. Canada
13.9. Market Attractiveness Analysis
13.9.1. By Product Type
13.9.2. By Application
13.9.3. By Route of Administration
13.9.4. By Types of Peptide
13.9.5. By Technology
13.9.6. By Manufacturing Type
13.9.7. By Country
14. Europe Peptide Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Product Type, 2020-2035
14.2.1. Innovative
14.2.2. Generic
14.3. Market Value Forecast By Application, 2020-2035
14.3.1. Metabolic
14.3.2. Oncology
14.3.3. Gastrointestinal
14.3.4. Cardiovascular
14.3.5. Neurological
14.3.6. Others
14.4. Market Value Forecast By Route of Administration, 2020-2035
14.4.1. Parenteral
14.4.2. Oral
14.4.3. Others
14.5. Market Value Forecast By Types of Peptide, 2020-2035
14.5.1. Native Peptides
14.5.2. Analog Peptides
14.5.3. Heterologous Peptides
14.6. Market Value Forecast By Technology, 2020-2035
14.6.1. Liquid Phase
14.6.2. Solid Phase
14.6.3. Hybrid
14.7. Market Value Forecast By Manufacturing Type, 2020-2035
14.7.1. In-house
14.7.2. CMO
14.8. Market Value Forecast By Country/Sub-region, 2020-2035
14.8.1. Germany
14.8.2. U.K.
14.8.3. France
14.8.4. Spain
14.8.5. Italy
14.8.6. Rest of Europe
14.9. Market Attractiveness Analysis
14.9.1. By Product Type
14.9.2. By Application
14.9.3. By Route of Administration
14.9.4. By Types of Peptide
14.9.5. By Technology
14.9.6. By Manufacturing Type
14.9.7. By Country/Sub-region
15. Asia Pacific Peptide Therapeutics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Product Type, 2020-2035
15.2.1. Innovative
15.2.2. Generic
15.3. Market Value Forecast By Application, 2020-2035
15.3.1. Metabolic
15.3.2. Oncology
15.3.3. Gastrointestinal
15.3.4. Cardiovascular
15.3.5. Neurological
15.3.6. Others
15.4. Market Value Forecast By Route of Administration, 2020-2035
15.4.1. Parenteral
15.4.2. Oral
15.4.3. Others
15.5. Market Value Forecast By Types of Peptide, 2020-2035
15.5.1. Native Peptides
15.5.2. Analog Peptides
15.5.3. Heterologous Peptides
15.6. Market Value Forecast By Technology, 2020-2035
15.6.1. Liquid Phase
15.6.2. Solid Phase
15.6.3. Hybrid
15.7. Market Value Forecast By Manufacturing Type, 2020-2035
15.7.1. In-house
15.7.2. CMO
15.8. Market Value Forecast By Country/Sub-region, 2020-2035
15.8.1. China
15.8.2. Japan
15.8.3. India
15.8.4. Australia & New Zealand
15.8.5. Rest of Asia Pacific
15.9. Market Attractiveness Analysis
15.9.1. By Product Type
15.9.2. By Application
15.9.3. By Route of Administration
15.9.4. By Types of Peptide
15.9.5. By Technology
15.9.6. By Manufacturing Type
15.9.7. By Country/Sub-region
16. Latin America Peptide Therapeutics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Product Type, 2020-2035
16.2.1. Innovative
16.2.2. Generic
16.3. Market Value Forecast By Application, 2020-2035
16.3.1. Metabolic
16.3.2. Oncology
16.3.3. Gastrointestinal
16.3.4. Cardiovascular
16.3.5. Neurological
16.3.6. Others
16.4. Market Value Forecast By Route of Administration, 2020-2035
16.4.1. Parenteral
16.4.2. Oral
16.4.3. Others
16.5. Market Value Forecast By Types of Peptide, 2020-2035
16.5.1. Native Peptides
16.5.2. Analog Peptides
16.5.3. Heterologous Peptides
16.6. Market Value Forecast By Technology, 2020-2035
16.6.1. Liquid Phase
16.6.2. Solid Phase
16.6.3. Hybrid
16.7. Market Value Forecast By Manufacturing Type, 2020-2035
16.7.1. In-house
16.7.2. CMO
16.8. Market Value Forecast By Country/Sub-region, 2020-2035
16.8.1. Brazil
16.8.2. Mexico
16.8.3. Rest of Latin America
16.9. Market Attractiveness Analysis
16.9.1. By Product Type
16.9.2. By Application
16.9.3. By Route of Administration
16.9.4. By Types of Peptide
16.9.5. By Technology
16.9.6. By Manufacturing Type
16.9.7. By Country/Sub-region
17. Middle East & Africa Peptide Therapeutics Market Analysis and Forecast
17.1. Introduction
17.1.1. Key Findings
17.2. Market Value Forecast By Product Type, 2020-2035
17.2.1. Innovative
17.2.2. Generic
17.3. Market Value Forecast By Application, 2020-2035
17.3.1. Metabolic
17.3.2. Oncology
17.3.3. Gastrointestinal
17.3.4. Cardiovascular
17.3.5. Neurological
17.3.6. Others
17.4. Market Value Forecast By Route of Administration, 2020-2035
17.4.1. Parenteral
17.4.2. Oral
17.4.3. Others
17.5. Market Value Forecast By Types of Peptide, 2020-2035
17.5.1. Native Peptides
17.5.2. Analog Peptides
17.5.3. Heterologous Peptides
17.6. Market Value Forecast By Technology, 2020-2035
17.6.1. Liquid Phase
17.6.2. Solid Phase
17.6.3. Hybrid
17.7. Market Value Forecast By Manufacturing Type, 2020-2035
17.7.1. In-house
17.7.2. CMO
17.8. Market Value Forecast By Country/Sub-region, 2020-2035
17.8.1. GCC Countries
17.8.2. South Africa
17.8.3. Rest of Middle East & Africa
17.9. Market Attractiveness Analysis
17.9.1. By Product Type
17.9.2. By Application
17.9.3. By Route of Administration
17.9.4. By Types of Peptide
17.9.5. By Technology
17.9.6. By Manufacturing Type
17.9.7. By Country/Sub-region
18. Competition Landscape
18.1. Market Player - Competition Matrix (By Tier and Size of companies)
18.2. Market Share Analysis By Company (2024)
18.3. Company Profiles
18.3.1. Amgen, Inc.
18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.1.2. Product Portfolio
18.3.1.3. Financial Overview
18.3.1.4. SWOT Analysis
18.3.1.5. Strategic Overview
18.3.2. Sachem Holding AG
18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.2.2. Product Portfolio
18.3.2.3. Financial Overview
18.3.2.4. SWOT Analysis
18.3.2.5. Strategic Overview
18.3.3. Eli Lilly and Company
18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.3.2. Product Portfolio
18.3.3.3. Financial Overview
18.3.3.4. SWOT Analysis
18.3.3.5. Strategic Overview
18.3.4. F. Hoffmann-La Roche Ltd.
18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.4.2. Product Portfolio
18.3.4.3. Financial Overview
18.3.4.4. SWOT Analysis
18.3.4.5. Strategic Overview
18.3.5. GlaxoSmithKline plc
18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.5.2. Product Portfolio
18.3.5.3. Financial Overview
18.3.5.4. SWOT Analysis
18.3.5.5. Strategic Overview
18.3.6. Novartis AG
18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.6.2. Product Portfolio
18.3.6.3. Financial Overview
18.3.6.4. SWOT Analysis
18.3.6.5. Strategic Overview
18.3.7. Pfizer, Inc.
18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.7.2. Product Portfolio
18.3.7.3. Financial Overview
18.3.7.4. SWOT Analysis
18.3.7.5. Strategic Overview
18.3.8. Sanofi
18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.8.2. Product Portfolio
18.3.8.3. Financial Overview
18.3.8.4. SWOT Analysis
18.3.8.5. Strategic Overview
18.3.9. Takeda Pharmaceutical Company Limited
18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
18.3.9.2. Product Portfolio
18.3.9.3. Financial Overview
18.3.9.4. SWOT Analysis
18.3.9.5. Strategic Overview
18.3.10. Teva Pharmaceutical Industries Ltd.
18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
